DEFA14A: ZimVie Reports Q2 2025, Set for ARCHIMED Buyout

ZimVie Inc. reported improved second-quarter 2025 financial results while confirming its definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash.

Summary

• ZimVie Inc. reported financial results for the quarter ended June 30, 2025.
• The company recently entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 in cash per share.
• Net sales from continuing operations for Q2 2025 were $116.7 million, a slight decrease of (0.1)% reported and (2.1)% in constant currency compared to Q2 2024.
• Net loss from continuing operations improved significantly to $(3.8) million in Q2 2025, compared to $(9.6) million in Q2 2024.
• Adjusted EBITDA from continuing operations increased to $17.5 million, or 15.0% of net sales, up from $15.8 million or 13.5% in Q2 2024.
• GAAP diluted EPS from continuing operations was $(0.14), while adjusted diluted EPS was $0.26 for Q2 2025.
• The acquisition is expected to close by year-end 2025, subject to stockholder and regulatory approvals, after which ZimVie will become a privately held company.
• Due to the pending transaction, ZimVie has withdrawn its fiscal 2025 guidance and will not host a conference call.

Sentiment

Score: 8

Explanation: The definitive agreement for acquisition at a fixed cash price of $19.00 per share provides a clear and positive outcome for shareholders, offering a premium and certainty. Additionally, the company's Q2 2025 financial results showed significant improvements in profitability metrics such as net loss, adjusted net income, adjusted diluted EPS, and adjusted EBITDA, despite a slight decline in net sales.

Positives

• Net loss from continuing operations significantly improved by $5.7 million, reducing from $(9.6) million in Q2 2024 to $(3.8) million in Q2 2025.
• Net loss margin improved by 490 basis points to (3.3)% in Q2 2025 from (8.2)% in Q2 2024.
• Adjusted net income increased by $3.6 million to $7.2 million in Q2 2025.
• Adjusted diluted EPS from continuing operations more than doubled to $0.26 in Q2 2025 from $0.13 in Q2 2024.
• Adjusted EBITDA from continuing operations increased by $1.6 million to $17.5 million in Q2 2025.
• Adjusted EBITDA margin improved by 150 basis points to 15.0% in Q2 2025.
• The definitive agreement to be acquired by ARCHIMED for $19.00 per share provides a clear cash exit for shareholders.

Negatives

• Net sales from continuing operations slightly decreased by (0.1)% on a reported basis and (2.1)% in constant currency compared to the prior year quarter.
• The company has withdrawn its fiscal 2025 guidance due to the pending acquisition, removing future financial visibility.
• The company will no longer be publicly traded on NASDAQ upon completion of the acquisition, limiting future public investment opportunities.

Risks

• The proposed acquisition by ARCHIMED may not be completed in a timely manner or at all.
• Failure to receive required approval from ZimVie's stockholders for the proposed transaction.
• Failure to satisfy or waive other conditions to the acquisition, including receipt of applicable regulatory approvals.
• The possibility of competing offers or acquisition proposals for ZimVie.
• The occurrence of any event that could lead to the termination of the definitive agreement, potentially requiring ZimVie to pay a termination fee.
• The pendency of the proposed transaction may negatively impact ZimVie's ability to attract, motivate, or retain key executives and employees.
• The pendency of the proposed transaction may affect ZimVie's ability to maintain relationships with customers, suppliers, and other business counterparties.
• The proposed transaction could divert management's attention from ongoing business operations.
• ZimVie's stock price may decline significantly if the proposed transaction is not consummated.
• Dependence on new product development, technological advances, and innovation.
• Shifts in product category or regional sales mix.
• Supply and prices of raw materials and products, including impacts from tariffs.
• Pricing pressures from competitors, customers, dental practices, and insurance providers.
• Changes in customer demand for products and services due to demographic changes or other factors.
• Challenges related to changes in and compliance with governmental laws and regulations affecting U.S. and international businesses, including FDA and foreign government regulators, and more stringent requirements for regulatory clearance of products.
• Competition in the dental implant market.
• Impact of healthcare reform measures and reductions in reimbursement levels by third-party payors.
• Cost containment efforts sponsored by government agencies, legislative bodies, the private sector, and healthcare group purchasing organizations, including the volume-based procurement process in China.
• Dependence on a limited number of suppliers for key raw materials and outsourced activities.
• Ability to obtain and maintain adequate intellectual property protection.
• Breaches or failures of information technology systems or products, including by cyberattack, unauthorized access, or theft.
• Ability to retain independent agents and distributors who market products.
• Ability to attract, retain, and develop highly skilled employees.
• Effect of mergers and acquisitions on relationships with customers, suppliers, and lenders, and on operating results.
• Potential determination by the Internal Revenue Service that the 2022 distribution of shares by Zimmer Biomet Holdings, Inc. or related transactions should be treated as taxable.
• Ability to form and implement alliances.
• Changes in tax obligations arising from tax reform measures or examinations by tax authorities.
• Product liability, intellectual property, and commercial litigation losses.
• Changes in general industry and market conditions, including domestic and international growth rates.
• Changes in general domestic and international economic conditions, including inflation, interest rate, and currency exchange rate fluctuations.
• Effects of global pandemics and other adverse public health developments on the global economy, business, and operations, including deferral of elective procedures and ability to collect accounts receivable.
• Impact of ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable.

Future Outlook

The company has withdrawn its fiscal 2025 guidance due to the pending acquisition by ARCHIMED. The transaction is expected to close by year-end 2025, at which point ZimVie will become a privately held company and its shares will no longer be publicly traded.

Management Comments

• Our results this quarter reflect the strength of our people and their unwavering commitment to executing our strategy and delivering for our customers and stakeholders.
• I would like to thank our entire team for their continued hard work and dedication.

Industry Context

ZimVie operates as a global life sciences leader in the dental implant market, developing and delivering products and solutions for dental tooth replacement and restoration. The pending acquisition by ARCHIMED indicates a consolidation trend or strategic investment interest in specialized medical device sectors, particularly those with established market positions like dental implants. This move suggests a private equity firm sees value in taking the company private, potentially to optimize operations away from public market pressures or integrate it into a larger portfolio.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess ZimVie's performance against global standards.
• The acquisition price of $19.00 per share by ARCHIMED suggests a valuation deemed attractive by a private equity firm specializing in healthcare, implying a perceived value proposition within the dental implant sector.
• Without specific industry averages for net sales growth, profitability margins, or EBITDA multiples for comparable dental implant companies, a detailed assessment against global benchmarks is not possible from this filing alone.

Stakeholder Impact

• Shareholders: Will receive $19.00 in cash per share upon completion of the acquisition, providing a liquidity event and a fixed return. Shares will be delisted from NASDAQ.
• Employees: The pendency of the transaction poses a risk to the company's ability to attract, motivate, or retain key executives and employees.
• Customers & Suppliers: The pendency of the transaction poses a risk to the company's ability to maintain relationships with its customers and suppliers.
• Regulatory Authorities: The transaction is subject to receipt of applicable regulatory approvals.

Next Steps

• ZimVie stockholders' approval of the acquisition.
• Receipt of applicable regulatory approvals for the acquisition.
• Expected closing of the acquisition by year-end 2025.
• Filing of ZimVie's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• Upon completion of the transaction, ZimVie will become a privately held company.
• Shares of ZimVie common stock will no longer be listed or publicly traded on the NASDAQ stock exchange.

Key Dates

Recommendation

The company has entered into a definitive agreement to be acquired for $19.00 in cash per share, with the transaction expected to close by year-end 2025. For existing shareholders, holding the stock until the acquisition closes allows them to realize the agreed-upon cash value, assuming the deal completes as expected. The financial results, while showing improved profitability, are secondary to the fixed acquisition price. For new investors, the arbitrage opportunity is limited by the fixed cash price and the remaining time until closing, making it less attractive for long-term investment.

Keywords

Dental Implants, Life Sciences, Medical Devices, Dental Health, Biomaterials, Digital Workflow, Acquisition, ARCHIMED, NASDAQ, SEC Filing, Financial Results, Earnings, ZIMV, Corporate Buyout